Coronary Intravascular Lithotripsy DRG 323 Reimbursement

DRG 323 addresses inpatient admissions for coronary intravascular lithotripsy with intraluminal device placement when a Major Complication or Comorbidity is present, encompassing complex percutaneous coronary interventions for calcified lesions. Correct classification affects inpatient reimbursement because the Diagnosis-Related Group assignment incorporates complication status to adjust payment for higher resource consumption.

DRG 323 Overview

DRG 323 covers inpatient admissions for coronary intravascular lithotripsy with placement of an intraluminal device and a Major Complication or Comorbidity, typically involving complex percutaneous coronary interventions for heavily calcified coronary lesions. This Diagnosis-Related Group is clinically focused on high-resource cardiovascular procedures with increased risk and length of stay due to the presence of a Major Complication or Comorbidity. It matters for Medicare payment because the presence of a Major Complication or Comorbidity increases relative reimbursement to reflect greater resource use and care intensity. Accurate clinical documentation and coding of the procedure and accompanying Major Complication or Comorbidity determine assignment to this Diagnosis-Related Group.

Acute procedural efficacy and safety studies of coronary intravascular lithotripsy (IVL) in high-risk calcified coronary lesions: prospective single-arm or randomized studies that evaluate immediate procedural outcomes (successful lesion modification, stent expansion, periprocedural myocardial infarction, major bleeding) in patients with severe coronary calcification undergoing percutaneous coronary intervention (PCI). These studies enroll patients with complex coronary anatomy, multivessel disease, or acute presentations who require intraluminal calcium modification prior to stent implantation, and they help define indications, procedural success rates, and short-term complication profiles relevant to interventional cardiology teams. Findings inform hospital resource allocation, peri-procedural care pathways, and payer assessments of the value and safety of using IVL devices in the inpatient setting for patients assigned to this DRG.
Comparative effectiveness trials versus alternative calcium-modification strategies during PCI: randomized or pragmatic trials comparing IVL to other intraluminal or atherectomy techniques (rotational/orbital atherectomy, scoring/cutting balloons) or adjunctive high-pressure ballooning in patients with severely calcified coronary lesions. These studies focus on clinically meaningful endpoints such as target lesion revascularization, stent thrombosis, long-term major adverse cardiovascular events, and device-related complications in diverse patient subgroups (including those with multivessel disease, chronic kidney disease, or acute coronary syndromes), providing head-to-head effectiveness data. Comparative effectiveness evidence is critical for clinicians choosing the optimal technique for index hospitalization and for payers and hospitals considering coverage policies, capital equipment investments, and cost-effectiveness of competing strategies for patients in this DRG.
Post-discharge longitudinal outcomes and health services research assessing functional recovery, readmission risk, and cost/resource utilization after IVL-enabled PCI: observational cohort studies and registry-based analyses that track medium- to long-term outcomes (90-day to multi-year), quality of life, rehospitalizations for cardiac causes, and subsequent reinterventions in patients who received intravascular lithotripsy during inpatient PCI. These studies often stratify by baseline comorbidity burden, complexity of coronary disease, and presence of major complications during index admission to identify predictors of readmission and durable clinical benefit. Results guide discharge planning, post-acute care pathways, bundled payment risk stratification, and payer decisions about post-discharge coverage and monitoring strategies for the population encompassed by this DRG.

Acute procedural efficacy and safety studies of coronary intravascular lithotripsy (IVL) in high-risk calcified coronary lesions: prospective single-arm or randomized studies that evaluate immediate procedural outcomes (successful lesion modification, stent expansion, periprocedural myocardial infarction, major bleeding) in patients with severe coronary calcification undergoing percutaneous coronary intervention (PCI). These studies enroll patients with complex coronary anatomy, multivessel disease, or acute presentations who require intraluminal calcium modification prior to stent implantation, and they help define indications, procedural success rates, and short-term complication profiles relevant to interventional cardiology teams. Findings inform hospital resource allocation, peri-procedural care pathways, and payer assessments of the value and safety of using IVL devices in the inpatient setting for patients assigned to this DRG.
Comparative effectiveness trials versus alternative calcium-modification strategies during PCI: randomized or pragmatic trials comparing IVL to other intraluminal or atherectomy techniques (rotational/orbital atherectomy, scoring/cutting balloons) or adjunctive high-pressure ballooning in patients with severely calcified coronary lesions. These studies focus on clinically meaningful endpoints such as target lesion revascularization, stent thrombosis, long-term major adverse cardiovascular events, and device-related complications in diverse patient subgroups (including those with multivessel disease, chronic kidney disease, or acute coronary syndromes), providing head-to-head effectiveness data. Comparative effectiveness evidence is critical for clinicians choosing the optimal technique for index hospitalization and for payers and hospitals considering coverage policies, capital equipment investments, and cost-effectiveness of competing strategies for patients in this DRG.
Post-discharge longitudinal outcomes and health services research assessing functional recovery, readmission risk, and cost/resource utilization after IVL-enabled PCI: observational cohort studies and registry-based analyses that track medium- to long-term outcomes (90-day to multi-year), quality of life, rehospitalizations for cardiac causes, and subsequent reinterventions in patients who received intravascular lithotripsy during inpatient PCI. These studies often stratify by baseline comorbidity burden, complexity of coronary disease, and presence of major complications during index admission to identify predictors of readmission and durable clinical benefit. Results guide discharge planning, post-acute care pathways, bundled payment risk stratification, and payer decisions about post-discharge coverage and monitoring strategies for the population encompassed by this DRG.

OpenPayer

Summary & Overview

Coronary Intravascular Lithotripsy with Intraluminal Device with MCC: Inpatient Reimbursement Overview

DRG 323 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes